Rising leader Mårten Steen, spoke with In Vivo about translating science into business, building precision medicine firms from the ground up and the importance of high-energy leadership.

This article was adapted from "Building Interventional Gynecology," which appeared in START-UP, June 2010.

Once a sluggish category for clinical innovation, gynecology is drawing new venture-backed companies eager to build upon the lead created by first-generation companies operating in minimally-invasive endometrial ablation and female sterilization. First generation companies had the difficult task of creating paths to early adopters of minimally invasive procedures. These now exist, and the clinical specialty appears to be also evolving in ways that encourage the growth of in-office procedures.

The Wellcome Trust will continue to help fund the early stages of drug discovery for another five years by extending its Seeding Drug Discovery initiative with a further £110 million.